AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Adenylate cyclase type 10 including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Adenylate cyclase type 10 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Adenylate cyclase type 10, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Adenylate cyclase type 10. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Adenylate cyclase type 10. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Adenylate cyclase type 10 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Adenylate cyclase type 10
partner:
Reaxense
upacc:
Q96PN6
UPID:
ADCYA_HUMAN
Alternative names:
AH-related protein; Adenylate cyclase homolog; Germ cell soluble adenylyl cyclase; Testicular soluble adenylyl cyclase
Alternative UPACC:
Q96PN6; B4DZF0; F5GWS5; O95558; Q5R329; Q5R330; Q8WXV4; Q9NNX0
Background:
Adenylate cyclase type 10, also known as AH-related protein, plays a pivotal role in cellular signaling by catalyzing the formation of cAMP, a crucial signaling molecule. This enzyme is instrumental in various physiological processes, including mammalian spermatogenesis, where it regulates nuclear factors essential for sperm maturation. Additionally, it is involved in ciliary beat regulation, highlighting its diverse functional significance in human biology.
Therapeutic significance:
Hypercalciuria absorptive 2, a condition marked by excessive urinary calcium excretion leading to calcium oxalate nephrolithiasis, is associated with variants affecting Adenylate cyclase type 10. Understanding the role of this protein could open doors to potential therapeutic strategies for managing this condition and improving patient outcomes.
